Remove sales-marketing white-papers
article thumbnail

Sales coaching: preparing for the new reality in pharma

pharmaphorum

COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment of how the sales function should work. The industry faces the dawn of a new age in sales coaching. This white paper explains how to adjust to it.

article thumbnail

Media means business

pharmaphorum

Havas Lynx Group’s 2020 white paper provides a blueprint for pharma brands to inject meaning into their media. Like so many others, the job of the pharma sales rep has been dramatically affected by the outbreak of COVID-19. The latter is the subject of our 2020 white paper, Media Means Business. About the author.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry

Pharma Marketing Network

Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry Content marketing is a long-term strategy that can help businesses of all sizes generate leads, increase brand awareness, and drive sales.

article thumbnail

A digital health roadmap for pharma, medical devices and insurance tech

pharmaphorum

The key trends for these sectors are identified and analysed in a new white paper from Healthware Group that offers guidance on how companies can best adjust to the new digital scenario. In the white paper, expert contributors share a detailed picture of the digital trends with the greatest potential to impact the near future.

article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K.

article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

article thumbnail

Oncology treatment decisions aren’t just based on clinical data

pharmaphorum

Yet how many other therapy areas have market leaders that don’t even have clinical approved indication in that indication? Michael’s areas of expertise span the clinical and commercial aspects of oncology markets. She has a good understanding of marketing strategy. The success of branding in immuno-oncology.

Cerner 98